Acurx Pharmaceuticals, Inc.

  • Home
  • About
    • Management / Consultants
    • Scientific / Corporate Advisors
    • Board of Directors
  • Pipeline
    • Overview
    • Ibezapolstat
    • ACX-375C
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Videos
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Ph2 Clinical Trial
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Videos

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Mar 16, 2023

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Mar 6, 2023

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023

Jan 16, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update

Nov 14, 2022

Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update

Nov 1, 2022

Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022

Oct 26, 2022

Acurx Announces Scientific Oral and Poster Presentations at IDWeek

Oct 17, 2022

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update

Aug 15, 2022

Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update

Aug 4, 2022

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

Aug 2, 2022
  • 1
  • 2
  • 3
  • 4
  • 5
© 2023 Acurx Pharmaceuticals, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap